logo
    • Magazine
    • Membership
    • Donate
  • Racial Justice
  • Economic Justice
  • Climate Justice
  • Health Justice
  • Leadership
  • CONTENT TYPES
  • Subscribe
  • Webinars
    • Free Webinars
    • Premium On-Demand Webinars
  • Membership
  • Submissions

An Ugly Profiteering Twist to the Sackler Story: Does It Take Eight to Tango?

Steve Dubb
April 2, 2019
Share
Tweet
Share
Email
Print
Jenny Mealing [CC BY 2.0], via Wikimedia Commons

April 1, 2019; New York Times

As NPQ has noted, lawsuits brought by Massachusetts and New York have named eight Sackler family members (in addition to a range of corporations) as defendants. These are, details the Times, “Kathe, Mortimer, Richard, Jonathan and Ilene Sackler Lefcourt—children of either Mortimer or Raymond Sackler—along with Theresa Sackler, the elder Mortimer’s widow; Beverly Sackler, Raymond’s widow; and David Sackler, a grandson of Raymond.” All told, the Sacklers now directly face lawsuits filed by more than 600 cities, counties, and Native American nations. Their company, Purdue Pharma, faces over 1,600 lawsuits.

The Sacklers, the New York Times remind us, are “a far-flung billionaire family that has a network of trusts and companies in the United States and abroad. Their philanthropic gifts have built namesake wings housing the Temple of Dendur at the Metropolitan Museum of Art in New York and oriental antiquities at the Louvre in Paris, as well as a library at the University of Oxford, and a scientific institute at Columbia University.” As of 2016, Forbes estimated their wealth at $13 billion. Last month, three museums—the National Portrait Gallery in London, London’s Tate Modern, and New York’s Guggenheim Museum—refused Sackler donations, and the Sackler Trust has said it will suspend new giving to avoid being a “distraction.”

Writing in the Times, Danny Hakim, Roni Caryn Rabin, and William K. Rashbaum highlight one more aspect of the Sackler story: an effort, launched in 2014 and codenamed Project Tango, that proposed that Purdue and the Sacklers could profit not only off the sale of OxyContin, but by selling drugs intended to help addicts wean themselves from OxyContin.

“The business potential of adding addiction treatment to the mix was illustrated in internal company charts and diagrams,” the Times explains. “Pain treatment and addiction are naturally linked,” noted one Project Tango document in the New York complaint. A funnel shows a fat end labeled “pain treatment” with a narrow end labeled “opioid addiction treatment.”

[Source: New York court filing]
The New York court documents also contend that a slide at a Purdue board meeting attended by Richard and Kathe Sackler advocated for Project Tango as follows, “It is an attractive market. Large unmet need for vulnerable, underserved, and stigmatized patient population suffering from substance abuse, dependence, and addiction.”

Sign up for our free newsletter

Subscribe to the NPQ newsletter to have our top stories delivered directly to your inbox.

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

The lawsuit adds:

  1. Defendant Kathe Sackler and Purdue’s Project Tango team reviewed findings that the “market” of people addicted to opioids had doubled from 2009 to 2014. Kathe and the staff found that the national catastrophe they caused provided an excellent compound annual growth rate (“CAGR”): “Opioid addiction (other than heroin) has grown by ~20 percent CAGR from 2000 to 2010.”

  2.  […]
  3. In February 2015, staff presented Kathe Sackler’s work on Project Tango to Purdue’s board. The plan was for a joint venture controlled by the Sacklers to sell the addiction medication suboxone and would result in the Sacklers’ acquisition of the “market lead [] in the addiction medicine space.”

“Purdue temporarily abandoned plans to pursue Project Tango in 2014,” Hakim and his colleagues write, “but revived the idea two years later, this time pursuing a plan to sell naloxone, an overdose-reversing drug, according to the Massachusetts filing. A few months later, in December 2016, Richard, Jonathan and Mortimer Sackler discussed buying a company that used implantable drug pumps to treat opioid addiction.”

The Sacklers, for their part, deny the allegations. The Times notes that a statement issued by “some of the Sacklers named in the suits” contends that “no board member proposed Tango or authored any documents in support of it.”—Steve Dubb

Share
Tweet
Share
Email
Print
ABOUT THE AUTHOR
Steve Dubb

Steve Dubb is a senior editor at NPQ, where he directs NPQ’s economic justice program, including NPQ’s Economy Remix column. Steve has worked with cooperatives and nonprofits for over two decades, including twelve years at The Democracy Collaborative and three years as executive director of NASCO (North American Students of Cooperation). In his work, Steve has authored, co-authored and edited numerous reports; participated in and facilitated learning cohorts; designed community building strategies; and helped build the field of community wealth building. Steve is the lead author of Building Wealth: The Asset-Based Approach to Solving Social and Economic Problems (Aspen 2005) and coauthor (with Rita Hodges) of The Road Half Traveled: University Engagement at a Crossroads, published by MSU Press in 2012. In 2016, Steve curated and authored Conversations on Community Wealth Building, a collection of interviews of community builders that Steve had conducted over the previous decade.

More about: Nonprofit Newsopioid addictionPolicy

Become a member

Support independent journalism and knowledge creation for civil society. Become a member of Nonprofit Quarterly.

Members receive unlimited access to our archived and upcoming digital content. NPQ is the leading journal in the nonprofit sector written by social change experts. Gain access to our exclusive library of online courses led by thought leaders and educators providing contextualized information to help nonprofit practitioners make sense of changing conditions and improve infra-structure in their organizations.

Join Today
logo logo logo logo logo
See comments

You might also like
Edgar Cahn’s Second Act: Time Banking and the Return of Mutual Aid
Steve Dubb
We Owe You Nothing: The Movement to Cancel Student Debt Gains Ground
Rithika Ramamurthy
Charitable Tax Reform: Why Half Measures Won’t Curb Plutocracy
Alan Davis
Green New Deal or Stale Old Tax-Break Scam? Getting Electric Vehicle Incentives Right
Greg LeRoy
Goodbye “Race Neutrality”—The Case for Race-Conscious Economic Policy
Dedrick Asante-Muhammad
Graduate Student Workers Are in the Frontline of the Growing Labor Movement
Rithika Ramamurthy

NPQ_Summer_2022

Upcoming Webinars

July 14th, 2 pm ET

Combating Disinformation and Misinformation in 21st-Century Social Movements

Register Now
Group Created with Sketch.
July 28th, 2 pm ET

Changing the Subject

Boards As Social Movement Spaces

Register Now
You might also like
Edgar Cahn’s Second Act: Time Banking and the Return of...
Steve Dubb
We Owe You Nothing: The Movement to Cancel Student Debt...
Rithika Ramamurthy
Charitable Tax Reform: Why Half Measures Won’t Curb...
Alan Davis

Like what you see?

Subscribe to the NPQ newsletter to have our top stories delivered directly to your inbox.

See our newsletters

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

Independent & in your mailbox.

Subscribe today and get a full year of NPQ for just $59.

subscribe
  • About
  • Contact
  • Advertise
  • Copyright
  • Careers

We are using cookies to give you the best experience on our website.

 

Non Profit News | Nonprofit Quarterly
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.